Wollina Uwe, Hansel Gesina, Koch André, Abdel-Naser Mohamed Badawy
Department of Dermatology, Academic Teaching Hospital Dresden-Friedrichstadt, Germany.
Expert Opin Pharmacother. 2006 Oct;7(14):1967-75. doi: 10.1517/14656566.7.14.1967.
Pimecrolimus is an ascomycin macrolactam. It is a specific calcineurin inhibitor that allows topical application. The highly lipophilic nature of this compound reduces the risk of systemic absorption through normal and inflammed skin. Pimecrolimus shows activity not only against T-cell activation, but also against mast cells and pruritus. Pimecrolimus 1% cream is approved for atopic dermatitis, and also has a great potential in other inflammatory skin diseases. Clinical trials have been performed in contact- and seborrhoeic dermatitis, genital lichen sclerosus, intertriginous psoriasis and cutaneous lupus erythematosus. In other diseases, the available data are limited to small case series, or individual cases of graft-versus-host disease or Netherton's disease. Although the use of calcineurin inhibitors in the treatment of vitiligo is promising, detailed studies with pimecrolimus and ultraviolet-irradiation are necessary and there is a need for prospective randomised, double-blind controlled trials.
吡美莫司是一种子囊霉素大环内酯类药物。它是一种允许局部应用的特异性钙调神经磷酸酶抑制剂。该化合物的高度亲脂性降低了通过正常皮肤和炎症皮肤进行全身吸收的风险。吡美莫司不仅对T细胞活化有活性，而且对肥大细胞和瘙痒也有活性。1%吡美莫司乳膏已被批准用于特应性皮炎，在其他炎症性皮肤病中也有很大潜力。已针对接触性皮炎、脂溢性皮炎、生殖器硬化性苔藓、间擦性银屑病和皮肤红斑狼疮开展了临床试验。在其他疾病中，现有数据仅限于小病例系列，或移植物抗宿主病或 Netherton 病的个别病例。尽管使用钙调神经磷酸酶抑制剂治疗白癜风前景广阔，但仍需要对吡美莫司和紫外线照射进行详细研究，并且有必要进行前瞻性随机双盲对照试验。
